New Processing Platforms Aim To Simplify Particle Manufacturing

Micropore Technologies Ltd, announced the launch of its next-generation integrated processing platforms.

Designed to bridge the gap between R&D formulation and full-scale production, Micropore’s HORIZON™ systems combine the company’s patented AXF™ technology into scalable, automated platforms designed to support particle engineering from development through to manufacturing for pharmaceuticals, CDMOs, fragrance or contract encapsulation houses.

Expertly created to address industry pain points, the HORIZON™’s continuous AXF™ technology enables controlled particle and droplet formation through low-shear emulsification and rapid intimate mixing, optimising reproducible and reliable results.

The systems are designed to maximise operational efficiency, with straightforward scale-up enabled through running longer batches and using larger vessels. In addition, sanitary construction and low holdup volumes allow faster cleaning between batches.

The HORIZON™ range is available in two standard systems: the HORIZON™mini, a compact system supporting development and pilot-scale production; and the HORIZON™one, an industrial-scale system designed for higher throughput applications. For specific production or regulatory requirements, Micropore Technologies offers the HORIZON™PRO, a bespoke build which can be custom designed.

Kay Hussain, CEO at Micropore Technologies, said: “The launch of the HORIZON™ range marks a fundamental shift in how complex formulations will move from the laboratory to production. By integrating our core AXF™ technology into an automated solution, we are further simplifying our customers’ journey from R&D to commercial scale. 

“Our standard and bespoke solutions will enable customers, regardless of industry, to accelerate time to market, at reduced risk and cost. It will provide the opportunity to optimise market share and beneficial patent lifetime whilst delivering positive improvements for end-users.”

The CMC Lead at a North American CDMO, said: “This is going to be the state of the art in microsphere manufacturing”.

As part of a collaborative Innovate UK-funded project focused on accelerating intracellular drug delivery, HORIZON™ systems were evaluated for lipid nanoparticle (LNP) formulation and scale-up.

Dr. Midhun Ben Thomas, Senior Scientist and Tech Lead at CPI, said: “The HORIZON™mini was used extensively in our RAP-IDD project and it generated monodispersed PolyA-LNP formulations with consistent CQAs across all experimental conditions. It performed flawlessly across a wide range of sample volumes, from 10mL to 10L, and delivered excellent results with diverse ionizable lipids, such as SM102, DLin-MC3-DMA and ALC-0315.

“The combination of scalability, robustness, and formulation consistency will make the HORIZON™mini an invaluable asset for industrial production. It will enable seamless scale-up from early-stage development to commercial manufacturing, eliminating the need for process re-optimisation and ensuring consistent CQAs from bench-top to production scale.” 

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.